fomivirsen sodium

Trade name: vitravene

Small moleculeapproved

Approved

Aug 26, 1998

Fomivirsen is an antisense antiviral drug that was used in the treatment of cytomegalovirus retinitis (CMV) in immunocompromised patients, including those with AIDS. It was administered via intraocular injection. — Wikipedia

Clinical trial activity

4 trials · 1 clinical orgs · 2 marketing orgs

Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0

Earliest trial started Nov 2, 1999 (NCT00002187)

Timeline

1990s

  1. Aug 26, 1998

    Ionis Pharmaceuticals, Inc. — Earliest FDA Approval

  2. Aug 26, 1998

    Ionis Pharmaceuticals, Inc. — NDA Organization

  3. Aug 26, 1998

    Novartis — NDA Secondary Org

  4. Jan 1, 1999

    Ionis Pharmaceuticals, Inc. — Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Approval history

  • approvedPriority reviewAug 26, 1998

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Discontinued

Oral

No

Parenteral

Yes

Topical

No

Sources

Also known as

  • fomivirisen
  • fomivirisen
  • fomivirsen
  • fomivirsen
  • fomivirsen
  • fomivirsen
  • fomivirsen
  • fomivirsen sodium
  • fomivirsen sodium
  • fomivirsen sodium
  • fomivirsen sodium
  • fomivirsen sodium
  • fomivirsen sodium
  • fomivirsen sodium
  • isis 2922
  • isis-2922
  • isis-2922
  • isis-2922
  • vitravene
  • vitravene
  • vitravene
  • vitravene

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00002156Phase 2Nov 2, 1999Ionis Pharmaceuticals, Inc.
NCT00002187N/ANov 2, 1999Ionis Pharmaceuticals, Inc.
NCT00002355N/ANov 2, 1999Ionis Pharmaceuticals, Inc.
NCT00002356Phase 2Nov 2, 1999Ionis Pharmaceuticals, Inc.
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Ionis Pharmaceuticals, Inc.For profit4421999
1 organizations
Page 1 / 1

Marketing (2)

OrganizationOrg typeRelationshipDate
Ionis Pharmaceuticals, Inc.For profitNDAAug 26, 1998
NovartisFor profitNDA2Aug 26, 1998